Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MNPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 403.74% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 204.01M USD | Price to earnings Ratio - | 1Y Target Price 53.27 |
Price to earnings Ratio - | 1Y Target Price 53.27 | ||
Volume (30-day avg) 36112 | Beta 1.19 | 52 Weeks Range 1.72 - 54.30 | Updated Date 04/1/2025 |
52 Weeks Range 1.72 - 54.30 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.98 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.42 | Actual -2.75 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.67% | Return on Equity (TTM) -112.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 214743888 | Price to Sales(TTM) - |
Enterprise Value 214743888 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6102530 | Shares Floating 2994199 |
Shares Outstanding 6102530 | Shares Floating 2994199 | ||
Percent Insiders 35.04 | Percent Institutions 42.25 |
Analyst Ratings
Rating 4.5 | Target Price 42 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Monopar Therapeutics Inc
Company Overview
History and Background
Monopar Therapeutics Inc. is a biopharmaceutical company primarily focused on developing innovative treatments for cancer and other serious diseases. Founded in 2011, it has focused on acquiring and developing promising therapeutic candidates.
Core Business Areas
- Oncogenesis-induced immune evasion: Developing treatments to reverse the mechanism of oncogenesis-induced immune evasion of tumors.
- Rare Disease Therapies: Focusing on the development of treatments for rare diseases, particularly focusing on rare diseases in children.
Leadership and Structure
The leadership team includes individuals with experience in pharmaceutical development, business development, and finance. The organizational structure is typical of a small biotech company.
Top Products and Market Share
Key Offerings
- Validiveu00ae: An approved product for the prevention of severe oral mucositis in patients receiving cancer treatment. The market for oral mucositis treatments is competitive, with companies like Galera Therapeutics and Soligenix also developing treatments.
- Camsirubicin: A late-stage clinical asset targeting soft tissue sarcoma. Competitors include companies like Eli Lilly and Bayer, who have existing therapies for soft tissue sarcoma.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high risk, high reward, and intense competition. It involves developing and commercializing new drugs, a process that requires significant investment and regulatory approvals.
Positioning
Monopar is positioned as a niche player focusing on specialized oncology and rare disease therapies. Their competitive advantage lies in their specific drug candidates and targeted approach.
Total Addressable Market (TAM)
The TAM for Monopar's targeted therapies can be in the billions of dollars. Monopar is attempting to capture a piece of this TAM with niche products and cancer treatment.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Experienced management team
- Established partnerships
- Specific focus on oncology and rare diseases
Weaknesses
- Limited financial resources
- High reliance on clinical trial success
- Dependence on partnerships for commercialization
- Small market capitalization
Opportunities
- Successful clinical trial outcomes
- Expansion into new therapeutic areas
- Strategic acquisitions or collaborations
- Orphan drug designation benefits
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expiration
Competitors and Market Share
Key Competitors
- GALE
- SLGN
Competitive Landscape
Monopar faces competition from larger pharmaceutical companies and other biotech firms. Its success depends on its ability to develop and commercialize innovative therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on past revenues and clinical trial results.
Future Projections: Future projections depend on successful development and commercialization of drug candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include clinical trial advancements and strategic collaborations.
Summary
Monopar Therapeutics is a small biopharmaceutical firm with a niche focus on oncology and rare diseases. Its success is heavily reliant on positive clinical trial outcomes and successful commercialization of its drug candidates. Limited financial resources and competition from larger players pose significant challenges. They need to carefully manage cash flow and focus on clinical trial advancement.
Similar Companies
- GALE
- SLGN
- KALA
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market Share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.monopartx.com |
Full time employees 9 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.